607707-75-5

Upstream product

• 607707-72-2 (2R,4'S,4S,5'R)-(4-methoxybenzenesulfonylamino)-(2',2',2,2-tetramethyl-[4',4]bis[[1,3]dioxolanyl]-5'-yl)-acetic acid methyl ester 

Downstream Products

• 607707-84-6 (3aR,4R,7S,7aR)-7-Hydroxy-5-(4-methoxy-benzenesulfonyl)-2,2-dimethyl-hexahydro-[1,3]dioxolo[4,5-c]pyridine-4-carboxylic acid hydroxyamide 
• 607707-81-3 (3aR,4R,7S,7aR)-7-hydroxy-5-(4'-methoxybenzenesulfonyl)-2,2-dimethyl-hexahydro-[1,3]dioxolo[4,5-c]pyridine-4-carboxylic acid methyl ester 
• 607707-78-8 (1S,2R,4'R,5'R)-[5'-(1-hydroxy-2-methanesulfonyloxyethyl)-2',2'-dimethyl-[1,3]dioxolan-4'-yl]-(4-methoxybenzenesulfonylamino)-acetic acid methyl ester 

Relevant academic research and scientific papers

NOVEL AZASUGAR DERIVATIVE AND DRUG CONTAINING THE SAME AS THE ACTIVE INGREDIENT

A novel azasugar derivative, and a drug containing the same as an active ingredient are disclosed. The drug is useful for treatment of keratinocyte-proliferative diseases.

Structure-activity relationships of azasugar-based MMP/ADAM inhibitors

In order to investigate structure-activity relationships of azasugar series toward metalloproteinases, we synthesized and evaluated several azasugar-based compounds. As a result, it was found that 4-phenoxybenzene derivative 3 having 2R,3R,4R,5S-configura